Novel nonchemotherapeutic agents have revolutionized treatment of hematological malignancies, especially in clinical settings where therapeutic options are limited. This is evidenced by accelerated FDA approval of BCL2 inhibitor, and ever expanding field of immunotherapeutics using checkpoint inhibitors and CAR-T cells. As we gain more knowledge, molecular laboratories will play a crucial role in identification on biomarkers of sensitivity and resistance to these agents for optimal implementation of precision medicine. This session will discuss the latest updates on the clinical utility, mechanisms of resistance, and innovative state-of-the-art strategies to assess responses in leukemia.
Targeting Immune Signaling Checkpoints in Acute Myeloid Leukemia
Ivana Gojo, MD, Johns Hopkins, Baltimore, MD, USA
Choosing Patient Therapy with Dynamic BH3 Profiling
Anthony Letai, MD, PhD, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA USA
Diverse Mechanisms of Acquired Resistance to CAR T Cell Immunotherapy
Andrei Thomas-Tikhonenko, PhD, Children's Hospital of Philadelphia, Philadelphia, PA, USA
Objectives:
- Describe the sensitivity and resistance patterns to immune check point inhibitors in AML and MDS.
- Understand the potential utility of dynamic BH3 profiling as a functional precision medicine tool.
- Understand the mechanisms of resistance to CD19-directed immunotherapies in B-lymphoblastic leukemias.
Duration: 1.50 hr
Recording Date: November 7, 2019
CME/CMLE credit: 1.50 hr
Last day to purchase course and CE claim credit: December 24, 2022
